As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Immix Biopharma. The largest reported stake is JANUS HENDERSON GROUP Ltd.'s, at 14%. 9 filings are on record since February 17, 2026 (Schedule 13G/A, August 13, 2026).
Sell to companies like Immix Biopharma? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 4,452,206 · Shared voting: 0 · Sole dispositive: 4,539,819 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: Eventide Asset Management, LLC · Sole voting: 3,891,019 · Shared voting: 0 · Sole dispositive: 3,891,019 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 9,783,192 · Sole dispositive: 0 · Shared dispositive: 9,783,192 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Janus Henderson Group Plc · Percent: 13% · SCHEDULE 13G/A
- · Holder: Janus Henderson Group Plc · Percent: 9.1% · SCHEDULE 13G/A
Immix Biopharma has 9 Schedule 13D or 13G filings on record since 2026-02-17. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 14% | 9,783,192 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Saturn V Capital Management LP | 6.97% | 3,693,585 | SCHEDULE 13G, 2026-02-17 | 2025-12-26 |
| Eventide Asset Management, LLC | 5.6% | 3,891,019 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 5.5% | 4,539,819 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Millennium Management LLC | 3.3% | 1,750,200 | SCHEDULE 13G/A, 2026-05-04 | 2026-03-31 |
Holding shares or following this stake? See who's behind Immix Biopharma and the warning signs.
Free to see. No signup.
Keep reading
More on Immix Biopharma and the records around it.
Immix Biopharma elsewhere on the record
Companies that share a holder
- Saturn V Capital Management LP also filed stake reports on 2 other companies: Monopar Therapeutics (Aug 2026), X4 Pharmaceuticals, Inc. (Feb 2026)
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026), COLLEGIUM PHARMACEUTICAL, INC (May 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Watch Immix Biopharma
Get an email when Immix Biopharma files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Immix Biopharma?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immix Biopharma: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immix Biopharma covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 0 | 9,783,192 | 0 | 9,783,192 | SCHEDULE 13G/A, 2026-08-13 |
| Eventide Asset Management, LLC | 3,891,019 | 0 | 3,891,019 | 0 | SCHEDULE 13G, 2026-08-14 |
| Finny Kuruvilla, M.D. Ph. D. | 0 | 3,891,019 | 0 | 3,891,019 | SCHEDULE 13G, 2026-08-14 |
| Robin C. John | 0 | 3,891,019 | 0 | 3,891,019 | SCHEDULE 13G, 2026-08-14 |
| BlackRock, Inc. | 4,452,206 | 0 | 4,539,819 | 0 | SCHEDULE 13G, 2026-10-27 |
The latest filing identifies Immix Biopharma by CUSIP 45258H106 and gives its principal executive office as 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064 (SCHEDULE 13G, 2026-10-27).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-17 | Saturn V Capital Management LP | 6.97% | SCHEDULE 13G |
| 2026-02-17 | Janus Henderson Group Plc | 7.4% | SCHEDULE 13G |
| 2026-03-20 | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2026-05-04 | Millennium Management LLC | 3.3% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 9.1% | SCHEDULE 13G/A |
| 2026-06-05 | Janus Henderson Group Plc | 13% | SCHEDULE 13G/A |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 14% | SCHEDULE 13G/A |
| 2026-08-14 | Eventide Asset Management, LLC | 5.6% | SCHEDULE 13G |
| 2026-10-27 | BlackRock, Inc. | 5.5% | SCHEDULE 13G |
Questions about who owns Immix Biopharma
Who owns Immix Biopharma?
On this page, 4 holders' latest ownership filings report 5% or more of Immix Biopharma: JANUS HENDERSON GROUP Ltd. (14%, Schedule 13G/A, filed 2026-08-13), Saturn V Capital Management LP (6.97%, Schedule 13G, filed 2026-02-17), Eventide Asset Management, LLC (5.6%, Schedule 13G, filed 2026-08-14) and BlackRock, Inc. (5.5%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Immix Biopharma?
By the share each holder's latest filing reports, the largest holders of Immix Biopharma on this page are JANUS HENDERSON GROUP Ltd. (14%), Saturn V Capital Management LP (6.97%) and Eventide Asset Management, LLC (5.6%).
When did JANUS HENDERSON GROUP Ltd. buy into Immix Biopharma?
The filings give report dates, not purchase dates. The earliest filing from JANUS HENDERSON GROUP Ltd. on this page is the Schedule 13G/A, filed 2026-08-13, reporting 14%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Immix Biopharma. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.